Bitnomial Exchange Self-Certifies First Ever U.S. Perpetual Futures Contracts
CHICAGO, April 23, 2025 /PRNewswire/ — Bitnomial, Inc., owner of Bitnomial Exchange, LLC—a CFTC-regulated Designated Contract Market (DCM)—today announced the self-certification of the first perpetual futures contracts ever listed on a U.S. exchange. Trading begins Monday, April 28, 2025, with the launch of BTC/USD perpetual futures, available initially to institutional participants.
Retail access will follow through the upcoming launch of Botanical, Bitnomial's new trading platform offering perpetual futures, traditional term futures, and options to both institutional and retail users. Additional contracts for XRP/USD, ETH/USD, SOL/USD, and other tokens and physical commodities are planned to follow.
'This is a pivotal moment,' said Luke Hoersten, Founder and CEO of Bitnomial. 'The U.S. is finally positioned to lead in regulated perpetual futures trading. With the launch of perpetuals and the Botanical platform, we're delivering the infrastructure our markets have needed—built from the ground up for both institutional and retail participants. Bitnomial is at the core of a once-in-a-century disruption to the quadrillion-dollar U.S. futures industry. We're not updating the system—we're resetting it.'
Bitnomial is the only U.S. exchange company offering physically delivered, non-synthetic exposure to crypto futures, options, and now perpetuals. The company is also preparing to launch perpetual futures settled in Ripple USD (RLUSD), a USD stablecoin—pending any necessary regulatory approvals. RLUSD-settled contracts will bring stablecoin-native margining and settlement directly into the core of regulated U.S. derivatives infrastructure.
Backed by leading institutional investors including Jump Capital, Electric Capital, Coinbase Ventures, Franklin Templeton, Ripple Labs, and DV Trading, Bitnomial is building the foundational infrastructure for the next generation of U.S. derivatives markets.
'Bitnomial's perpetual futures are built with eight-hour funding rate intervals, matching the market structure used by offshore venues that dominate crypto derivatives volume,' said Michael Dunn, President of Bitnomial Exchange. 'This structural parity allows traders to integrate Bitnomial seamlessly into their existing trading systems—bringing familiar mechanics to a fully regulated U.S. marketplace.'
About Bitnomial, Inc.
Bitnomial, Inc. is a digital asset derivatives exchange company that owns and operates U.S. CFTC-regulated exchange (DCM), clearinghouse (DCO), and brokerage (FCM) subsidiaries. Bitnomial offers the Bitcoin Complex® comprising physically delivered Bitcoin Futures, Options, and Hashrate Futures.
Follow Bitnomial at bitnomial.com and on X @bitnomialFollow Botanical at botanical.finance and on X @botanical
Media Contact:media@bitnomial.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Contact Levi & Korsinsky Before July 15, 2025 to Discuss Your Rights
NEW YORK, June 6, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Krispy Kreme, Inc. ('Krispy Kreme, Inc.' or the 'Company') (NASDAQ: DNUT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Krispy Kreme, Inc. investors who were adversely affected by alleged securities fraud between February 25, 2025 and May 7, 2025. Follow the link below to get more information and be contacted by a member of our team: DNUT investors may also contact Joseph E. Levi, Esq. via email at jlevi@ or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) demand for Krispy Kreme products declined materially at McDonald's locations after the initial marketing launch; (2) demand at McDonald's locations was a driver of declining average sales per door per week; (3) the partnership with McDonald's was not profitable; (4) the foregoing posed a substantial risk to maintaining the partnership with McDonald's; (5) as a result, the Company would pause expansion into new McDonald's locations; and (6) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. WHAT'S NEXT? If you suffered a loss in Krispy Kreme, Inc. during the relevant time frame, you have until July 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004jlevi@ Tel: (212) 363-7500Fax: (212)
Malaysian Reserve
5 hours ago
- Malaysian Reserve
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 6, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ('Zenas BioPharma, Inc.' or the 'Company') (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Follow the link below to get more information and be contacted by a member of our team: ZBIO investors may also contact Joseph E. Levi, Esq. via email at jlevi@ or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. WHAT'S NEXT? If you suffered a loss in Zenas BioPharma, Inc. during the relevant time frame, you have until June 16, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004jlevi@ (212) 363-7500Fax: (212)
Malaysian Reserve
11 hours ago
- Malaysian Reserve
Jack Henry CFO Mimi Carsley to Participate in Morgan Stanley Conference
MONETT, Mo., June 6, 2025 /PRNewswire/ — Jack Henry & Associates, Inc.® (Nasdaq: JKHY) announced today that it will be participating in the upcoming conference: Mimi Carsley, CFO & Treasurer, will present at the Morgan Stanley US Financials Conference on June 11. The presentation takes place at 1 p.m. ET. A live webcast of the presentation will be accessible on the Morgan Stanley website. A replay will be available on following the live presentation. About Jack Henry & Associates, Inc.®Jack Henry™ (Nasdaq: JKHY) is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. We are an S&P 500 company that prioritizes openness, collaboration, and user centricity – offering banks and credit unions a vibrant ecosystem of internally developed modern capabilities as well as the ability to integrate with leading fintechs. For nearly 50 years, Jack Henry has provided technology solutions to enable clients to innovate faster, strategically differentiate, and successfully compete while serving the evolving needs of their accountholders. We empower approximately 7,500 clients with people-inspired innovation, personal service, and insight-driven solutions that help reduce the barriers to financial health. Additional information is available at Statements made in this news release that are not historical facts are 'forward-looking statements.' Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, those discussed in the Company's Securities and Exchange Commission filings, including the Company's most recent reports on Form 10-K and Form 10-Q, particularly under the heading 'Risk Factors.' Any forward-looking statement made in this news release speaks only as of the date of the news release, and the Company expressly disclaims any obligation to publicly update or revise any forward-looking statement, whether because of new information, future events or otherwise.
